Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
By L. De Mattos-Arruda, R. Mayor, C. Ng, B. Weigelt, F. Martínez-Ricarte, D. Torrejon, Mafalda Oliveira, A. Arias, C. Raventós, Jiabin Tang and 20 more. Nature Communications, 2015
753 citations recorded by the source corpus.
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. However, patients with brain tumours do not present with or present with low amounts of ctDNA in plasma precluding the genomic characterization of brain cancer through plasma ctDNA. Here we show that ctDNA derived from central nervous system tumours is more abundantly present in the cerebrospinal fluid (CSF) than in plasma. Massively parallel sequencing of CSF ctDNA more comprehensively characterizes the genomic alterations of brain tumours than plasma, allowing the identification of actionable brain tumour somatic mutations. We show that CSF ctDNA levels longitudinally fluctuate in time and follow the changes in brain tumour burden providing biomarkers to monitor brain malignancies. Moreover, CSF ctDNA is shown to facilitate and complement the diagnosis of leptomeningeal carcinomatosis. DNA circulating in the plasma of cancer patients carries features of the primary tumour, however such DNA is found in low levels in brain cancer patients. Here, the authors show that circulating tumour DNA can be detected in the cerebral spinal fluid of cancer patients and that this better recapitulates the primary tumour compared to DNA from the plasma.
Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/7598834e9d1e77891b9e0d34e770ead3a01b6305
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Integrated digital error suppression for improved detection of circulating tumor DNA (2016, positive): “Similar patterns of recurrent errors were also present in independently generated cfDNA sequencing data 18 , suggesting a common artifact (Supplementary Fig.”
- Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, positive): “Moreover, mutations undetected by conventional tissue sampling have been screened using ctDNAs from LBs [105].”